Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma.

Filippi AR, Ciammella P, Piva C, Ragona R, Botto B, Gavarotti P, Merli F, Vitolo U, Iotti C, Ricardi U.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):370-5. doi: 10.1016/j.ijrobp.2014.01.041. Epub 2014 Mar 7.

PMID:
24613810
2.

Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.

Lu NN, Li YX, Wu RY, Zhang XM, Wang WH, Jin J, Song YW, Fang H, Ren H, Wang SL, Liu YP, Liu XF, Chen B, Dai JR, Yu ZH.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):210-6. doi: 10.1016/j.ijrobp.2011.11.008. Epub 2012 Mar 19.

PMID:
22436783
3.

Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.

Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, Lynch J, Li Z, Mendenhall NP.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):260-7. doi: 10.1016/j.ijrobp.2011.06.1959. Epub 2011 Oct 17.

PMID:
22014950
4.

Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.

Hoppe BS, Flampouri S, Zaiden R, Slayton W, Sandler E, Ozdemir S, Dang NH, Lynch JW, Li Z, Morris CG, Mendenhall NP.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1053-9. doi: 10.1016/j.ijrobp.2014.04.029. Epub 2014 Jun 10.

6.

Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.

Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, Engelholm SA.

Radiat Oncol. 2014 Feb 4;9:44. doi: 10.1186/1748-717X-9-44.

7.

Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.

Enrici RM, Anselmo AP, Donato V, Falchetto Osti M, Santoro M, Tombolini V, Mandelli F.

Haematologica. 1999 Oct;84(10):917-23.

8.

Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.

Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, van Herk M, Heemsbergen WD.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):737-44. doi: 10.1016/j.ijrobp.2014.12.017.

PMID:
25752386
9.

Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.

Torok JA, Wu Y, Prosnitz LR, Kim GJ, Beaven AW, Diehl LF, Kelsey CR.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):54-9. doi: 10.1016/j.ijrobp.2015.02.003.

PMID:
25863754
10.

Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations.

Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, Borca VC, Ragona R, Tofani S, Ricardi U.

Radiat Oncol. 2012 Nov 2;7:186. doi: 10.1186/1748-717X-7-186.

11.

Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):94-102. Epub 2007 Feb 22.

PMID:
17321067
12.

A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?

Hamed RH, Anter AH, Awad IA.

Hematol Oncol Stem Cell Ther. 2012;5(1):36-41. doi: 10.5144/1658-3876.2012.36.

13.

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

Colonna P, Jais JP, Desablens B, Harousseau JL, Brière J, Boasson M, Lemevel A, Casassus P, Le Prisé PY, Guilhot F, Ghandour C, Lejeune F, Andrieu JM.

J Clin Oncol. 1996 Jun;14(6):1928-35.

PMID:
8656262
14.

Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.

Filippi AR, Ragona R, Piva C, Scafa D, Fiandra C, Fusella M, Giglioli FR, Lohr F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):161-8. doi: 10.1016/j.ijrobp.2015.02.030.

PMID:
25863763
15.

ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.

Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A; Intergruppo Italiano Linfomi (IIL).

Ann Oncol. 2008 Apr;19(4):763-8. doi: 10.1093/annonc/mdm575. Epub 2008 Jan 6.

16.

Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.

Brusamolino E, Lazzarino M, Orlandi E, Canevari A, Morra E, Castelli G, Alessandrino EP, Pagnucco G, Astori C, Livraghi A, et al.

Ann Oncol. 1994;5 Suppl 2:101-6.

PMID:
7515642
17.

Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.

Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT.

Cancer. 2010 Aug 15;116(16):3943-52. doi: 10.1002/cncr.25246.

18.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.

N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067.

19.

Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.

Elconin JH, Roberts KB, Rizzieri DA, Vermont C, Clough RW, Kim C, Dodge RK, Prosnitz LR.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1097-105.

PMID:
11072168
20.

Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.

Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-83. doi: 10.1016/j.ijrobp.2015.04.021. Epub 2015 Apr 17.

PMID:
26031367
Items per page

Supplemental Content

Write to the Help Desk